Journal of the European Academy of Dermatology and Venereology最新文献

{"title":"Efficacy and safety of biologics for hidradenitis suppurativa: A network meta-analysis of phase III trials.","authors":"Laura Calabrese, Alessandra Cartocci, Pietro Rubegni, Lars E French, Benjamin Kendziora","doi":"10.1111/jdv.20617","DOIUrl":"10.1111/jdv.20617","url":null,"abstract":"<p><strong>Background: </strong>Phase III clinical trials are designed to evaluate the therapeutic effect of drugs and their superiority over other treatment methods, but biologics for hidradenitis suppurativa (HS) have not been compared head-to-head in phase III studies.</p><p><strong>Objectives: </strong>To evaluate the relative efficacy and safety of biologics for HS in a network meta-analysis including available data from phase III trials.</p><p><strong>Methods: </strong>MEDLINE and Embase were searched for phase III trials investigating the efficacy and/or safety of at least one biologic for moderate-to-severe HS. The odds ratios for reaching an HS Clinical Response 50 (HiSCR50) and for the occurrence of adverse events after 12-16 weeks were compared between treatments.</p><p><strong>Results: </strong>PIONEER I and II (adalimumab 40 mg weekly vs. placebo), SUNSHINE and SUNRISE (secukinumab 300 mg every 2 vs. 4 weeks vs. placebo) as well as BE HEARD I and II (bimekizumab 320 mg every 2 vs. 4 weeks vs. placebo) with 2731 patients were included. Adalimumab weekly was ranked most effective in reaching a HiSCR50 with significant superiority over secukinumab every 2 weeks (OR = 1.74; 95% confidence interval [CI]: 1.11-2.73) and 4 weeks (OR = 1.72; 95% CI: 1.09-2.7) and insignificant superiority over bimekizumab every 2 weeks (OR = 1.23; 95% CI: 0.74-2.06) and 4 weeks (OR = 1.25; 95% CI: 0.73-2.14). Adalimumab showed the fewest adverse events with significant superiority over bimekizumab every 2 weeks (OR = 0.52; 95% CI: 0.32-0.86) and insignificant superiority over bimekizumab every 4 weeks (OR = 0.79; 95% CI: 0.47-1.33) and secukinumab every 2 weeks (OR = 0.69; 95% CI: 0.45-1.07) and 4 weeks (OR = 0.71; 95% CI: 0.46-1.1).</p><p><strong>Conclusions: </strong>Among currently approved biologic agents for moderate-to-severe HS, adalimumab demonstrated the highest efficacy and safety in the first 12-16 weeks of treatment.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":" ","pages":"637-645"},"PeriodicalIF":8.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014433/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mind–skin interactions in chronic hand eczema: A call for integrated dermatologic practice","authors":"Katlein França","doi":"10.1111/jdv.70329","DOIUrl":"10.1111/jdv.70329","url":null,"abstract":"&lt;p&gt;Chronic hand eczema (CHE) is a frequent, often persistent inflammatory condition characterized by erythema, scaling, fissures and substantial discomfort of the hands. This condition occurs in both occupational and non-occupational settings and commonly follows a long, relapsing course that interferes with daily tasks, work performance, and impacts quality of life. The causes for CHE develop through a combination of genetic susceptibility, barrier disruption, immune activation, environmental irritants or allergens, and psychosocial stress.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Despite the prevalence of chronic hand eczema and the availability of advanced treatments, many patients still experience inadequate disease control and persistent symptoms. Balato and colleagues, from the European Academy of Dermatology &amp; Venereology Contact Dermatitis Task Force, published a comprehensive manuscript addressing frequent clinical questions and discussing topics such as the etiopathogenetic and epidemiologic background, clinical features, differential diagnosis, diagnostic workup, disease course, prognosis and scoring, the impact on quality of life and psychosocial and economic status, preventive strategies, and both established and emerging treatments for CHE. Among the newer pharmacological options are crisaborole, roflumilast, apremilast, AFX5931, dupilumab, tralokinumab, and lebrikizumab. The authors highlight that some of these agents are approved for other conditions but have demonstrated efficacy when used off-label in chronic hand eczema, while others have recently received approval or are expected to receive approval soon, specifically for this indication.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Growing evidence shows that CHE cannot be adequately understood or treated through a purely dermatologic lens. Multiple studies now document that CHE carries a substantial psychiatric and psychosocial burden, with patients experiencing significantly elevated rates of anxiety, depression, social anxiety and avoidance behaviours&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; A recent meta-analysis strengthens this conclusion, demonstrating that individuals with hand eczema consistently exhibit moderate-to-severe quality-of-life impairment and higher anxiety scores compared with healthy controls&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Psychosocial distress can be out of proportion to clinical severity. When taken together, these data show that CHE is not merely a localized skin inflammatory disorder but a biopsychosocial condition in which psychological state, stress biology, immune activation and skin barrier integrity continually interact. This perspective supports reshaping CHE management to routinely include psychosocial screening tools, stress-reduction strategies, referral to cognitive-behavioural interventions and evaluation of how comorbid anxiety or depression may influence the response to advanced systemic therapies such as JAK inhibitors or biologics. Dermatologists have the unique opportunity to provide ear","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"554-555"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.70329","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From canvas to clinic: Atopic clues in Van Gogh's Boy with an Orange","authors":"Guillermo Roa Álvarez,&nbsp;Sergio Enrique Leal Osuna","doi":"10.1111/jdv.70215","DOIUrl":"10.1111/jdv.70215","url":null,"abstract":"&lt;p&gt;Vincent van Gogh (1853–1890) stands among the most influential painters in Western art. During the brief, feverish months between his discharge from the asylum at Saint-Rémy and his death in July 1890, he vowed to paint “one canvas a day,” capturing more than 70 works in Auvers-sur-Oise.&lt;span&gt;&lt;sup&gt;1, 2&lt;/sup&gt;&lt;/span&gt; Amid those turbulent final weeks, &lt;i&gt;Boy with an Orange&lt;/i&gt; (Figure 1) offers an unexpected island of calm.&lt;/p&gt;&lt;p&gt;The portrait depicts Raoul Levert, the carpenter's small son, seated in a meadow dotted with yellow blooms, gently rolling a bright orange between his hands.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Unlike Van Gogh's brooding self-portraits of the same period, the scene radiates innocence and serenity, perhaps reflecting the tenderness he felt for his newborn nephew, also named Vincent, whose arrival is documented in his letters.&lt;span&gt;&lt;sup&gt;2-4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Van Gogh's vigorous, impasto brushwork accentuates the boy's rosy malar cheeks, sharply contrasted against the otherwise pale complexion. The erythema is bilaterally symmetrical, spares the perioral skin, and carries a faint sheen suggestive of mild exudation, hallmarks that invite a modern dermatologist to consider early-childhood atopic dermatitis (AD).&lt;/p&gt;&lt;p&gt;Nonetheless, any diagnosis based on a painting remains speculative. Alternative causes for the child's facial erythema merit consideration. For example, ulerythema or even a mild juvenile dermatomyositis.&lt;span&gt;&lt;sup&gt;5-7&lt;/sup&gt;&lt;/span&gt; Another point of ambiguity is the sitter's gender: &lt;i&gt;Boy with an Orange&lt;/i&gt; indeed portrays a male toddler (Raoul Levert), yet the child's long smock and delicate features give a feminine impression. Such gender-neutral attire was customary for young children in the 1890s, potentially confusing modern viewers.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;By Van Gogh's time, chronic childhood eczema was clinically recognized but poorly understood. Late 19th-century physicians like Hebra and Besnier documented relapsing, intensely itchy rashes in children (often dubbed “prurigo” in severe cases) and even noted occasional links to asthma or “hay fever,” foreshadowing the atopic triad.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; However, this dermatosis lacked a unifying concept or cure; its immunological basis was unknown, and the term “atopic dermatitis” would not be coined until the 20th century. Treatment in the late 19th century remained empirical, centered on emollient salves, baths, and avoidance of suspected irritants.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Thus, although eczema was a familiar childhood affliction, its aetiology remained elusive.&lt;/p&gt;&lt;p&gt;Seen through this lens, &lt;i&gt;Boy with an Orange&lt;/i&gt; may document more than pastoral childhood. The lush meadow and profusion of wildflowers that frame Raoul could symbolize a potential aggravating factor; pollen is a notorious aero-allergen in atopic children.&lt;span&gt;&lt;sup&gt;5, 8&lt;/sup&gt;&lt;/span&gt; In addition, the bright orange itself, rich in citrus oils, might have irritated sensitive skin. In a 1","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"574-575"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdv.70215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145644617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From ‘nice to have’ to ‘must have’: Integrating ultrasound into routine care of hidradenitis suppurativa","authors":"Eva Vilarrasa","doi":"10.1111/jdv.70312","DOIUrl":"10.1111/jdv.70312","url":null,"abstract":"&lt;p&gt;Hidradenitis suppurativa (HS) is characterized by a striking mismatch between what is visible on the skin surface and the true extent of the disease in the dermis and subcutis. Over the last decade, high-frequency and ultra-high-frequency ultrasound (US) have progressively revealed this ‘hidden HS’, providing objective information on tunnels, fluid collections, pseudocysts and follicular alterations that are frequently missed during physical examination alone. The international Delphi consensus by Wortsman et al. represents a crucial step in transforming this body of work into standardized, pragmatic recommendations for daily practice and research in HS.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;As a dermatologist dedicated to HS management, surgery and cutaneous ultrasound, I strongly welcome this consensus. The authors assembled an experienced, truly international panel of HS-US experts across four continents and achieved high levels of agreement on indications, technical requirements, key lesions, scoring systems and pre-interventional planning.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This validates what many of us have observed in daily practice: ultrasound is no longer an optional add-on, but an indispensable tool to correctly stage, monitor and treat HS.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Clinically, the most immediate impact is the explicit recommendation to use US to support diagnosis and staging. Multiple studies have shown that purely bedside scores tend to underestimate HS severity compared with sonographic scores.&lt;span&gt;&lt;sup&gt;2, 3&lt;/sup&gt;&lt;/span&gt; By identifying subclinical tunnels, interconnected fluid collections and deep inflammation, bedside US frequently ‘upstages’ patients—especially those labelled Hurley I–II—clarifying bioeligibility for targeted systemic treatment and helping define a therapeutic ‘window of opportunity’ for early disease interception, before irreversible fibrotic tunnelling.&lt;span&gt;&lt;sup&gt;2-4&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;From a surgical perspective, I particularly endorse the recommendation to use US for preoperative and procedural mapping and evaluation of postoperative complications.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Ultrasound-guided delineation of tunnels improves the accuracy of excision, supports preservation of key anatomical structures, reduces the risk of residual disease and helps anticipate reconstruction needs.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Beyond anatomy, US supports therapeutic decision-making on timing and sequencing of medical therapy, interventional management or a planned medical-procedural combination. It refines tunnel phenotyping beyond ‘draining/non-draining’ by capturing features such as oedema, Doppler signal, fibrosis and possible internal epithelialization; all of which have prognostic implications (e.g. the ‘double rail/railway’ sign).&lt;span&gt;&lt;sup&gt;3-5&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Perhaps the most forward-looking aspect of the statement is the call to systematically integrate US into HS clinical trials and longitudinal cohorts.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"560-561"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ME3183, an oral phosphodiesterase 4 inhibitor, in patients with plaque psoriasis","authors":"Kim A. Papp,&nbsp;April W. Armstrong,&nbsp;Tomokazu Koresawa,&nbsp;Kazunari Otake,&nbsp;Masayuki Hirata,&nbsp;Akiko Kano","doi":"10.1111/jdv.20863","DOIUrl":"10.1111/jdv.20863","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There is an unmet need for oral psoriasis medications with improved efficacy and safety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We evaluated the efficacy and safety of oral ME3183, a novel phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a randomized, double-blind, placebo-controlled study with a 16-week double-blind treatment period. Patients were randomly assigned (1:1:1:1:1) to oral ME3183 5 mg twice daily (BID), 10 mg once daily (QD), 7.5 mg BID, 15 mg QD or placebo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 132 patients were randomly assigned to ME3183 5 mg BID (26 patients), 10 mg QD (26 patients), 7.5 mg BID (26 patients), 15 mg QD (27 patients) and placebo (27 patients). The proportions of patients achieving ≥75% reduction in baseline Psoriasis Area and Severity Index scores at Week 16 (primary endpoint) were 58.3%, 32.0%, 61.5% and 52.0% in each ME3183 group, respectively, versus 14.8% in the placebo group (all <i>p</i> &lt; 0.01 vs. placebo, except for the 10 mg QD group). The most common adverse events across the ME3183 groups were diarrhoea (16.0%–38.5%), nausea (7.7%–30.8%) and headache (7.7%–42.3%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>ME3183 should be further investigated as a safe and effective treatment alternative for moderate to severe plaque psoriasis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"610-616"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144719369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics for treatment of paediatric plaque psoriasis: A systematic review and network meta-analysis","authors":"Abdullah Ali Aljalfan,&nbsp;Muhammad Talha Maniya,&nbsp;Dilshad Sachedina,&nbsp;Serene Raaed Almuhaidib,&nbsp;Abdulmajeed Sulaiman Alharbi,&nbsp;Rahmah Alamrie,&nbsp;Umna Aziz,&nbsp;Anusha Abdul Muqeet Farid","doi":"10.1111/jdv.70084","DOIUrl":"10.1111/jdv.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Objectives</h3>\u0000 \u0000 <p>As biologic therapy is increasingly being utilized in the treatment of paediatric psoriasis, we aim to perform a systematic review and network meta-analysis to compare the efficacy and safety of available biologic treatments for moderate to severe paediatric plaque psoriasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Relevant randomized controlled trials (RCTs) were searched for in PubMed, Embase, Cochrane CENTRAL and clinicaltrials.gov. We performed a fixed-effects frequentist network meta-analysis (NMA) with the surface under the cumulative ranking curve (SUCRA) calculated for and mean ranking calculated. The main outcomes of interest were a ≥75% improvement in PASI score (PASI75), ≥90% improvement in PASI score (PASI90), 100% improvement in PASI score (PASI100), CDLQI score of 0/1 (CDLQI 0/1) at weeks 12–16 and safety outcomes at 12–20 weeks. Point probabilities of response were also calculated, presented as absolute risk differences per 1000 patients with their 95% CIs compared to placebo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seven RCTs comprising 1016 psoriasis patients were included. Compared to placebo, all biologic therapies exhibited a significantly higher PASI90 and PASI75 response. Based on the SUCRA, Ixekizumab ranked highest in achieving the PASI100 (SUCRA: 0.9, Mean Rank: 1.8) response. Secukinumab high dose ranked the best for PASI90 (SUCRA: 0.8, Mean Rank: 3.0). For the CDLQI 0/1 (SUCRA: 0.8, Mean Rank: 2.2) response and the PASI75 (SUCRA: 0.9, Mean Rank: 2.2) response, standard dose Ustekinumab exhibited superior performance.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>All biologic agents (not including non-biologic comparators methotrexate and FAEs) were significantly superior to placebo, with no significant difference between individual biologic therapies, for the treatment of moderate-to-severe paediatric plaque psoriasis. Ixekizumab and Secukinumab demonstrated a trend towards a higher PASI90 response, while Ustekinumab showed a trend towards increased CDLQI and PASI75 responses. These findings highlight the need for better-powered trials in this population to determine the optimal treatment modality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> PROSPERO Number</h3>\u0000 \u0000 <p>CRD42023476983.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"597-609"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145294994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term safety and efficacy in paediatric psoriasis: Remaining challenges","authors":"Catherine Droitcourt,&nbsp;Ninon Le Goaziou","doi":"10.1111/jdv.70333","DOIUrl":"10.1111/jdv.70333","url":null,"abstract":"&lt;p&gt;Psoriasis is a common disease, including in children, particularly from the age of 10 years. It is a chronic and stigmatizing condition,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; which requires long-term and targeted treatment, including in the paediatric population. Consequently, long-term data on efficacy and safety are essential. A recent study by Kaszuba et al.,&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; sponsored by Novartis (secukinumab), provides the longest follow-up data currently available for any biologic in children with severe psoriasis (over more than 4 years). Biologics—particularly anti-IL-17 agents—are attractive therapeutic options in the paediatric population because they require less frequent injections and minimal laboratory monitoring.&lt;/p&gt;&lt;p&gt;With the increasing number of biologics now available for the treatment of children with psoriasis, long-term data are particularly needed in this population to guide the choice of systemic treatment in clinical practice. In addition to secukinumab (monoclonal antibody targeting interleukin 17A), several other biologics have been approved by the European Medical Agency (EMA) for the management of psoriasis in paediatric population: anti-TNF alpha agents (etanercept from age of 6 years and adalimumab from age of 4 years), ustekinumab (monoclonal antibody anti-ILs12/23, from age of 6 years), ixekizumab (monoclonal antibody anti-interleukin 17A, from age of 6 years)&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; and followed very recently by guselkumab (monoclonal antibody anti-interleukin 23, from age of 6 years). In total, six EMA-approved biologics are currently recommended as first-line treatment options in children and adolescents with moderate-to-severe psoriasis. Despite this expansion of biologics use in chronic inflammatory skin diseases, there are only few data regarding long-term biologic use in children with psoriasis (data with etanercept and ixekizumab).&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; This study referenced offers important insights into long-term safety.&lt;/p&gt;&lt;p&gt;The safety data of this study are particularly reassuring. Data on long-term safety are indeed needed: biologic therapies have been introduced more recently in children than in adults, and adult data&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; cannot be directly extrapolated to the paediatric population; the clinical trials that supported marketing authorization do not allow for the assessment of outcomes specific to children—particularly linear growth and pubertal development—given their limited duration; preschool- and school-aged children are at higher risk of infections, and the regular updates to their vaccination schedules require particular attention.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;In terms of efficacy, although the PASI has been used in clinical trials, extrapolating this outcome to the paediatric population may be inappropriate. For instance, the PASI may be less suitable for children, as their lesions are often lighter in colour and less scaly. Finally, from a pathophysiological perspecti","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"558-559"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic hand eczema: Common questions and practical recommendations from the EADV Contact Dermatitis Task Force","authors":"Anna Balato,&nbsp;Vittorio Tancredi,&nbsp;Olivier Aerts,&nbsp;Marie-Noëlle Crépy,&nbsp;Aleksandra Dugonik,&nbsp;Margarida Gonçalo,&nbsp;Beata Krecisz,&nbsp;Suzana Ljubojevic Hadzavdic,&nbsp;Laura Malinauskienė,&nbsp;Esen Özkaya,&nbsp;Dagmar Simon,&nbsp;Ana Maria Giménez-Arnau","doi":"10.1111/jdv.70068","DOIUrl":"10.1111/jdv.70068","url":null,"abstract":"<p>Chronic hand eczema (CHE) is a prevalent and complex skin condition that can significantly affect patients' quality of life (QoL) and social and occupational functioning. In this review structured as questions and answers format, we aimed to target the main topics of CHE including etiopathogenetic-epidemiologic background, clinical findings, differential diagnosis/diagnostic assessment, course–prognosis and scoring, impact on QoL and psycho-socio-economic status, prevention and treatment. CHE may result from irritant contact dermatitis (ICD), allergic contact dermatitis (ACD), atopic dermatitis (AD) or other unclassified causes and is often related to occupational exposure, especially in environments with frequent water exposure. CHE can manifest in various forms, with distinct clinical and aetiological subtypes, which helps both in diagnosis and treatment. The epidemiology of CHE is probably widely underreported, but it has a higher incidence in women, though it tends to be more severe in men. Genetic predisposition plays a role, but environmental factors, particularly in occupational settings, are key contributors. Pathogenetically, CHE involves different but overall similar immune responses depending on the subtype, including both Th1, Th2 and innate immune system reactions, alongside to chronic skin barrier dysfunction. The impact of CHE on QoL is comparable to other chronic conditions, with significant psycho-social and economic consequences, including work absenteeism and increased healthcare costs. Preventive strategies focus on avoiding trigger factors and promoting proper hand care, while treatment involves a combination of topical and systemic therapies. Non-pharmacological measures like moisturizers, topical corticosteroids and calcineurin inhibitors are common treatments. Recent advances in the development of biologics, including JAK inhibitors, show promise for moderate to severe cases, although their safety and efficacy remain under investigation. While current treatments aim to manage symptoms, there is an urgent need for further research into the pathogenesis of CHE to enable the development of more targeted and effective long-term therapies.</p>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"583-596"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145188266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results","authors":"Andrzej Kaszuba,&nbsp;Philemon Papanastasiou,&nbsp;Dorota Krasowska,&nbsp;Raul De Lucas Laguna,&nbsp;Michael Ziv,&nbsp;Shoba Ravichandran,&nbsp;Amita Bansal,&nbsp;Swapnil S. Dahale,&nbsp;Ruvie Martin,&nbsp;Bertrand Paguet,&nbsp;Nina Magnolo,&nbsp;Kulli Kingo","doi":"10.1111/jdv.70155","DOIUrl":"10.1111/jdv.70155","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Plaque psoriasis, a chronic inflammatory disease, affects up to 2.1% of the global paediatric population. In a Phase 3 study (NCT02471144), secukinumab treatment for up to 104 weeks demonstrated good tolerability and efficacy in paediatric patients with severe chronic plaque psoriasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Final long-term safety and efficacy results of secukinumab through 236 weeks of treatment in paediatric patients with severe chronic plaque psoriasis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>During the extension period (Weeks 52–236), paediatric patients aged 6 to &lt;18 years with severe chronic plaque psoriasis received either ‘Any secukinumab’ low dose (LD; patients receiving secukinumab LD up to Week 52; patients on placebo who transitioned to secukinumab LD) or ‘Any secukinumab’ high dose (HD; patients receiving secukinumab HD up to Week 52 and patients on placebo who transitioned to secukinumab HD). Assessments included Psoriasis Area and Severity Index (PASI) 75/90/100 responses, Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 response, relapse, rebound, Children's Dermatology Life Quality Index (CDLQI) score, CDLQI 0/1 response and long-term safety up to Week 236.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Secukinumab maintained efficacy through 236 weeks of treatment, with consistent responses observed in most assessments across both dose groups. At Week 236, the responder rate for IGA mod 2011 0/1 was 69.4% (‘Any secukinumab’ LD) and 79.5% (‘Any secukinumab’ HD); the PASI 75/90/100 responses were 97.2%/77.8%/50.0% (‘Any secukinumab’ LD) and 97.4%/84.6%/69.2% (‘Any secukinumab’ HD). CDLQI 0/1 responses remained consistent in both dose groups and were maintained up to Week 236 (‘Any secukinumab’ LD: 64.3%; ‘Any secukinumab’ HD: 67.7%). The most common adverse events were nasopharyngitis (EAIR/100 PYs [95% CI]:13.9 [10.0, 18.7]), headache (5.8 [3.7, 8.8]) and tonsillitis (4.7 [2.8, 7.4]). <i>Candida</i> infections were reported in 3 patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings support the sustained efficacy and favourable safety profile of secukinumab in paediatric patients with severe plaque psoriasis over a 236-week treatment period.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"617-625"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145524882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric psoriasis and biologics: An evidence gap in plain sight","authors":"Stephan Traidl,&nbsp;Sascha Gerdes","doi":"10.1111/jdv.70309","DOIUrl":"10.1111/jdv.70309","url":null,"abstract":"&lt;p&gt;Despite the broad armamentarium of effective biologic therapies available for the treatment of moderate-to-severe psoriasis in adults, and the recent initiation of discussions on potential disease modification or even curing,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; therapeutic options for children and adolescents remain comparatively limited.&lt;/p&gt;&lt;p&gt;Aljalfan et al. provide a rigorous synthesis of the available randomized controlled trials for biologic therapies in paediatric plaque psoriasis and highlights this persistent imbalance.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Psoriasis is not uncommon in childhood. Population-based studies estimate a prevalence of approximately 0.5%–1% among children and adolescents, with up to one third of patients experiencing disease onset before the age of 18.&lt;span&gt;&lt;sup&gt;3, 4&lt;/sup&gt;&lt;/span&gt; Beyond visible skin involvement, paediatric psoriasis is associated with substantial physical and psychosocial burden, impaired quality of life and early trajectories of cardiometabolic and inflammatory comorbidities.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; Nevertheless, the therapeutic evidence base in this age group remains markedly narrower than that established for adult patients.&lt;/p&gt;&lt;p&gt;Against this background, the network meta-analysis by Aljalfan et al. represents an important contribution. Across randomized controlled trials, biologic therapies demonstrated meaningful efficacy and acceptable short-term safety in children and adolescents with moderate-to-severe plaque psoriasis. The analysis also highlights structural limitations, including small trial numbers, limited sample sizes and few direct comparisons, necessitating cautious interpretation of treatment rankings.&lt;/p&gt;&lt;p&gt;The findings also underscore a central discrepancy between adult and paediatric psoriasis care. In adults, multiple biologics targeting TNFα, IL-17 and IL-23 are approved and routinely used.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; In contrast, paediatric approvals are confined to a limited subset of these agents and specific age categories, despite shared disease biology. Consequently, treatment decisions in children often rely on extrapolation from adult data and are still frequently constrained by slower regulatory timelines and restricted labelling.&lt;/p&gt;&lt;p&gt;In addition, paediatric-specific guidance remains limited. Existing European recommendations acknowledge the usefulness of biologics in children and adolescents with moderate-to-severe disease when conventional systemic treatment is inadequate or inappropriate.&lt;span&gt;&lt;sup&gt;5, 6&lt;/sup&gt;&lt;/span&gt; However, the guideline also highlights the limited paediatric trial data underpinning these recommendations. Updated guidelines are urgently needed—ideally aligning paediatric therapeutic goals more closely with those used in adults. Importantly, these goals should include, where feasible, complete or near-complete skin clearance as a realistic treatment target. The findings of the present meta-analysis underline that several already approved paediatric biologics","PeriodicalId":17351,"journal":{"name":"Journal of the European Academy of Dermatology and Venereology","volume":"40 4","pages":"556-557"},"PeriodicalIF":8.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13014436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}